胃复春片联合奥美拉唑肠溶胶囊治疗功能性消化不良的临床疗效

康年松; 黄戬; 钱蓉; 谷红苹; 韩旭丰; 苏文涛

doi:10.16766/j.cnki.issn.1674-4152.003459

胃复春片联合奥美拉唑肠溶胶囊治疗功能性消化不良的临床疗效

doi: 10.16766/j.cnki.issn.1674-4152.003459

康年松^1, ,,
黄戬²,
钱蓉³,
谷红苹⁴,
韩旭丰⁴,
苏文涛⁵

1.
余姚市中医医院治未病科, 浙江余姚 315400
2.
余姚市人民医院消化内科, 浙江余姚 315400
3.
余姚市人民医院康复医学科
4.
余姚市中医医院内科
5.
余姚市中医医院中医内科

基金项目:

浙江省中青年临床名中医项目浙中医药[2021]22号

浙江省医学会临床科研基金项目 2020ZYC-B0

详细信息

通讯作者:
康年松, E-mail: kangniansong@163.com

中图分类号: R57 R975.2
计量
- 文章访问数: 137
- HTML全文浏览量: 63
- PDF下载量: 10
- 被引次数: 0
出版历程
- 收稿日期: 2023-10-31
- 网络出版日期: 2024-05-29

Clinical effect of Weifuchun tablets combined with omeprazole enteric-coated capsules in the treatment of functional dyspepsia

1.
Department of Treatment of Disease Department, Yuyao Hospital of Traditional Chinese Medicine, Yuyao, Zhejiang 315400, China

摘要

摘要: 目的探讨胃复春片联合奥美拉唑肠溶胶囊治疗功能性消化不良患者的临床效果，及其对血清胃蛋白酶原、胃泌素17的影响。方法采用随机数字表法将余姚市中医医院2021年10月—2022年12月收治的128例功能性消化不良患者分为胃复春组与莫沙必利组, 每组各64例。莫沙必利组给予奥美拉唑联合莫沙必利片治疗，胃复春组给予奥美拉唑联合胃复春片治疗，连续治疗4周后，比较2组患者的治疗效果、血清胃蛋白酶原、胃泌素17水平等。结果治疗4周后，胃复春组(87.50%, 56/64)的治疗总有效率高于莫沙必利组(71.88%, 46/64，χ²=4.827，P < 0.05)；胃复春组胃蛋白酶原Ⅰ[(113.20±10.21)μg/L]水平高于莫沙必利组[(98.26±9.64)μg/L，P < 0.05]，胃蛋白酶原Ⅱ[(17.21±2.58)μg/L]、胃泌素17[(15.31±2.09)pmol/L]水平均低于莫沙必利组[(20.31±3.11)μg/L、(18.22±2.67)pmol/L，P < 0.05]。结论胃复春片联合奥美拉唑肠溶胶囊治疗功能性消化不良患者临床症状改善明显，且能纠正血清胃蛋白酶原、胃泌素17水平的异常，提高患者的预后生活质量。
- 功能性消化不良 /
- 胃复春片 /
- 血清胃蛋白酶原 /
- 奥美拉唑 /
- 胃泌素17
Abstract: Objective To explore the clinical effect of Weifuchun tablets combined with omeprazole enteric-coated capsules on patients with functional dyspepsia and their influence on serum pepsinogen and gastrin-17 levels. Methods Using a random number table, 128 patients diagnosed with functional dyspepsia at Yuyao Hospital of Traditional Chinese Medicine between October 2021 and December 2022 were divided into two groups: Weifuchun group and Mosapride group, eaching consisting of 64 cases. The mosapride group was given a combination of omeprazole and Mosapride tablets, while the Weifuchun group was given a combination of omeprazole and Weifuchun tablets. After 4 weeks of continuous treatment, the therapeutic effect, serum pepsinogen, and gastrin-17 levels were compared between the two groups. Results After 4 weeks of treatment, the Weifuchun group demonstrated a higher total effective rate (87.50%, 56/64) compared to the Mosapride group (71.88%, 46/64), with a statistically significant difference (χ²=4.827, P < 0.05). The Weifuchun group also exhibited higher levels of pepsinogen Ⅰ [(113.20±10.21) μg/L] compared to the Moxapride group [(98.26±9.64) μg/L, P < 0.05]. Moreover, the Weifuchun group showed lower levels of pepsinogen Ⅱ[(17.21±2.58) μg/L] and gastrin-17 [(15.31±2.09) pmol/L] compared to the Mosapride group [(20.31±3.11) μg/L, (18.22±2.67) pmol/L, P < 0.05]. Conclusion The combination of Weifuchun tablets and omeprazole enteric-coated capsules significantly improves the clinical symptoms of patients with functional dyspepsia. It effectively corrects abnormal levels of serum pepsinogen and gastrin-17, leading to improved prognosis and enhanced quality of life for patients.
- Functional dyspepsia /
- Weifuchun tablets /
- Serum pepsinogen /
- Omeprazole /
- Gastrin-17

HTML全文

表 1 2组功能性消化不良患者中医症状积分比较(x ± s，分)

Table 1. Comparison of TCM symptom scores between two groups of patients with functional dyspepsia(x ± s, points)

组别	例数	餐后饱胀不适		早饱感		中上腹痛		中上腹烧灼感
组别	例数	治疗前	4周后	治疗前	4周后	治疗前	4周后	治疗前	4周后
莫沙必利组	64	7.57±1.68	4.46±0.81^b	7.01±1.67	4.78±0.94^b	6.83±1.28	4.18±0.67^b	7.16±1.21	3.86±1.03^b
胃复春组	64	7.61±1.25	1.82±0.35^b	7.19±1.42	1.41±0.39^b	7.05±1.41	2.02±0.57^b	6.87±1.79	1.24±0.33^b
统计量		0.153^a	91.701^c	0.657^a	156.152^c	0.924^a	40.898^c	1.074^a	81.055^c
P值		0.879	< 0.001	0.512	< 0.001	0.357	< 0.001	0.285	< 0.001
注：^a为t值，^c为F值；与同组治疗前比较，^bP < 0.05。

下载: 导出CSV

表 2 2组功能性消化不良患者中医症候疗效比较[例(%)]

Table 2. Comparison of curative effect of TCM symptoms between two groups of patients with functional dyspepsia[cases(%)]

组别	例数	显效	有效	无效	总有效
莫沙必利组	64	20(31.25)	26(40.63)	18(28.12)	46(71.88)
胃复春组	64	31(48.44)	25(39.06)	8(12.50)	56(87.50)
注：2组疗效比较，Z=6.238，P=0.442；2组总有效率比较，χ²=4.827，P=0.028。

下载: 导出CSV

表 3 2组功能性消化不良患者生活质量改善情况比较(x ± s，分)

Table 3. Comparison of quality of life improvement between two groups of patients with functional dyspepsia (x ± s, points)

组别	例数	躯体功能		精神状况		社会认知
组别	例数	治疗前	4周后	治疗前	4周后	治疗前	4周后
莫沙必利组	64	60.52±3.26	78.56±7.26^b	35.12±3.65	57.15±6.22^b	55.26±4.31	67.45±6.20^b
胃复春组	64	61.27±4.52	85.26±6.88^b	36.84±4.11	63.25±5.86^b	54.67±5.12	74.52±5.21^b
统计量		1.077^a	27.143^c	2.503^a	44.386^c	0.705^a	49.512^c
P值		0.284	< 0.001	0.014	< 0.001	0.482	< 0.001
注：^a为t值，^c为F值；与同组治疗前比较，^bP < 0.05。

下载: 导出CSV

表 4 2组功能性消化不良患者血清胃蛋白酶原、胃泌素17水平比较(x ± s)

Table 4. Comparison of serum pepsinogen and gastrin 17 levels between two groups of patients with functional dyspepsia(x ± s)

组别	例数	胃蛋白酶原Ⅰ(μg/L)		胃蛋白酶原Ⅱ(μg/L)		胃泌素17(pmol/L)
组别	例数	治疗前	4周后	治疗前	4周后	治疗前	4周后
莫沙必利组	64	80.11±6.21	98.26±9.64^b	25.61±4.12	20.31±3.11^b	21.03±3.26	18.22±2.67^b
胃复春组	64	79.68±7.16	113.20±10.21^b	26.02±3.26	17.21±2.58^b	20.86±2.88	15.31±2.09^b
统计量		0.363^a	52.753^c	0.624^a	17.283^c	0.313^a	21.890^c
P值		0.717	< 0.001	0.534	< 0.001	0.755	< 0.001
注：^a为t值，^c为F值；与同组治疗前比较，^bP < 0.05。

下载: 导出CSV

参考文献(26)

[1]	MEDIĆ B, BABIĆ Ž, BANIĆ M, et al. Modern approach to dysplasia[J]. Acta Clin Croat, 2021, 60(4): 731-738.
[2]	WAUTERS L, SLAETS H, DE PAEPE K, et al. Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(10): 784-792. doi: 10.1016/S2468-1253(21)00226-0
[3]	戴一青, 王金金, 张磊, 等. 心理治疗对老年功能性消化不良患者消化功能及心理状态的影响[J]. 中华全科医学, 2021, 19(10): 1710-1712, 1716. doi: 10.16766/j.cnki.issn.1674-4152.002148 DAI Y Q, WANG J J, ZHANG L, et al. Effect of psychotherapy on digestive function and psychological state of elderly patients with functional dyspepsia[J]. Chinese Journal of General Practice, 2021, 19(10): 1710-1712, 1716. doi: 10.16766/j.cnki.issn.1674-4152.002148
[4]	WEI X, YU J, XU Z K, et al. Incidence, pathogenesis, and management of proton pump inhibitor-Induced Nephrotoxicity[J]. Drug Saf, 2022, 45(7): 703-712. doi: 10.1007/s40264-022-01181-4
[5]	王龙华, 王凤磊, 李静, 等. 功能性消化不良的中医辨治思路与对策[J]. 中华中医药杂志, 2021, 36(9): 5368-5371. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202109066.htm WANG L H, WANG F L, LI J, et al. Thought of syndrome differentiation and countermeasures in Chinese medical treatment of functional dyspepsia[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2021, 36(9): 5368-5371. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202109066.htm
[6]	YOON J Y, KO S J, PARK J W, et al. Complementary and alternative medicine for functional dyspepsia: an Asian perspective[J]. Medicine (Baltimore), 2022, 101(35): e30077. DOI: 10.1097/MD.0000000000030077.
[7]	AZIMI M, ZAHEDI M J. Persian herbal medicine in functional dyspepsia: a systematic review[J]. Curr Drug Discov Technol, 2021, 18(2): 272-281. doi: 10.2174/1570163817666200611132831
[8]	YANG L J, HU Z P, ZHU J J, et al. Effects of weifuchun tablet for chronic atrophic gastritis: a protocol for systematic review and meta-analysis[J]. Medicine (Baltimore), 2020, 99(22): e20374. DOI: 10.1097/MD.0000000000020374.
[9]	WANG H J, WU R M, XIE D, et al. A Combined phytochemistry and network pharmacology approach to reveal the effective substances and mechanisms of wei-fu-chun tablet in the treatment of precancerous lesions of gastric cancer[J]. Front Pharmacol, 2020, 11: 558471. DOI: 10.3389/fphar.2020.558471.
[10]	中华中医药学会脾胃病分会, 张声生. 功能性消化不良中医诊疗专家共识意见(2017)[J]. 中华中医药杂志, 2017, 32(6): 2595-2598. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202403106.htm Spleen and Stomach Diseases Branch of Chinese Medicine Association, ZHANG S S. Expert Consensus on the Diagnosis and Treatment of Functional dyspepsia (2017)[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2017, 32(6): 2595-2598. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202403106.htm
[11]	国家中医药管理局. 中医病证诊断疗效标准[S]. 南京: 南京大学出版社, 1994: 233-234. National Administration of Traditional Chinese Medicine. Diagnostic criteria of TCM diseases and syndromes[S]. Nanjing: Nanjing University Press, 1994: 233-234.
[12]	郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002: 295. ZHENG X Y. Guiding Principles for Clinical Research of New Chinese Medicine (Trial)[M]. Beijing: China Medical Science and Technology Press, 2002: 295.
[13]	WILLIAMSON A, HOGGART B. Pain: a review of three commonly used pain rating scales[J]. J Clin Nurs, 2005, 14(7): 798-804. doi: 10.1111/j.1365-2702.2005.01121.x
[14]	严啸天, 王旭. "化浊生新膏"治疗FESS术后鼻黏膜上皮化45例临床研究[J]. 江苏中医药, 2019, 51(3): 33-35. doi: 10.3969/j.issn.1672-397X.2019.03.013 YAN X T, WWANG X. Clinical study of "Huazhuo Shengxin ointment" in treating 45 cases of nasal mucosa epithelialization after FESS[J]. Jiangsu Traditional Chinese Medicine, 2019, 51(3): 33-35. doi: 10.3969/j.issn.1672-397X.2019.03.013
[15]	LUGTENBERG R T, DE GROOT S, KAPTEIN A A, et al. Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial[J]. Breast Cancer Res Treat, 2021, 185(3): 741-758. doi: 10.1007/s10549-020-05991-x
[16]	KAMIYA T, OSAGA S, KUBOTA E, et al. Questionnaire-based survey on epidemiology of functional gastrointestinal disorders and current status of gastrointestinal motility testing in asian countries[J]. Digestion, 2020, 102(1): 73-89. doi: 10.3969/j.issn.1672-2159.2020.01.016
[17]	BORDBAR G, MIRI M B, OMIDI M, et al. Comparison of a novel herbal medicine and omeprazole in the treatment of functional dyspepsia: a randomized double-blinded clinical trial[J]. Gastroenterol Res Pract, 2020, 2020: 5152736. DOI: 10.1155/2020/5152736.
[18]	姚鹏, 冯璐, 郝莉莉, 等. 西尼必利联合胃复春片治疗慢性萎缩性胃炎的临床研究[J]. 现代药物与临床, 2020, 35(12): 2441-2445. https://www.cnki.com.cn/Article/CJFDTOTAL-GWZW202012031.htm YAO P, FENG L, HAO L L, et al. Clinical study on the treatment of chronic atrophic gastritis with cilazapril combined with Weifuchun tablets[J]. Modern Medicine and Clinic, 2020, 35(12): 2441-2445. https://www.cnki.com.cn/Article/CJFDTOTAL-GWZW202012031.htm
[19]	GU Z J, LING J H, CONG J, et al. A review of therapeutic effects and the pharmacological molecular mechanisms of chinese medicine weifuchun in treating precancerous gastric conditions[J]. Integr Cancer Ther, 2020, 19: 1534735420953215. DOI:10.1177/1534735 420953215.
[20]	PORTER K M, HOEY L, HUGHES C F, et al. Associations of atrophic gastritis and proton-pump inhibitor drug use with vitamin B-12 status, and the impact of fortified foods, in older adults[J]. Am J Clin Nutr, 2021, 114(4): 1286-1294. doi: 10.1093/ajcn/nqab193
[21]	PAPAKONSTANTINOU I P, KARAKOUSIS N D, ANDREADIS E A. Gastric neuroendocrine tumour, atrophic gastritis and autoimmune haemolytic anaemia: a case report and review[J]. Scott Med J, 2019, 64(4): 154-158. doi: 10.1177/0036933019867574
[22]	CITTOLIN-SANTOS G F, KHALIL S, BAKOS J K, et al. Chronic atrophic gastritis with negative intrinsic factor and parietal cell antibody presenting as a severe hemolytic anemia[J]. Case Rep Hematol, 2020, 2020: 8697493. DOI: 10.1155/2020/8697493.
[23]	PELLICANO R. Is chronic atrophic gastritis the missing link between atrophic glossitis, gastric parietal cell antibody positivity and hematological deficiencies?[J]. J Formos Med Assoc, 2020, 119(5): 1004-1005. doi: 10.1016/j.jfma.2020.01.003
[24]	LIU H X, FEI C R, ZHANG J. Associations of serum pepsinogens and helicobacter pylori infection with high-sensitivity C-reactive protein in medical examination population[J]. Lab Med, 2021, 52(1): 57-63. doi: 10.1093/labmed/lmaa042
[25]	LI X L, FENG M X, YUAN G. Clinical efficacy of Weisu granule combined with Weifuchun tablet in the treatment of chronic atrophic gastritis and its effect on serum G-17, PG Ⅰ and PG Ⅱ levels[J]. Am J Transl Res, 2022, 14(1): 275-284.
[26]	白文筠, 梁峻尉, 苗秀明, 等. 穴位埋线联合四联疗法对幽门螺旋杆菌(+)脾胃虚弱证慢性萎缩性胃炎的疗效观察[J]. 针刺研究, 2022, 47(6): 537-543. https://www.cnki.com.cn/Article/CJFDTOTAL-XCYJ202206011.htm BAI W J, LIANG J W, MIAO X M, et al. Clinical effects of acupoint catgut embedding with quadruple therapy on Hp(+)chronic atrophic gastritis of spleen and stomach deficiency syndrome[J]. Acupuncture Research, 2022, 47(6): 537-543. https://www.cnki.com.cn/Article/CJFDTOTAL-XCYJ202206011.htm